Status: Institutional editorial perspective, not peer-reviewed research or a real-time shortage bulletin.
The decision agenda
MSI’s next stage is to connect its ten-domain framework with evidence records that decision-makers can inspect. Our priority is to define the question, show the source and separate observed conditions from proposed responses.
Three priorities
- Governance: specify who owns a medicines-security risk and how it reaches accountable leaders.
- Capability: distinguish announced facilities from viable production, workforce and recovery capacity.
- Intelligence: attach provenance, dates and uncertainty to signals before recommending action.
Evidence to build on
The UK government’s medicines-supply paper connects shortage mitigation with wider resilience. Its accompanying data pack offers a historical baseline. WHO’s AI guidance provides a foundation for accountable health technology. These sources inform our research questions; they do not validate an MSI Index.
- DHSC and NHS England: Managing a robust and resilient supply of medicines (2025)
- Accompanying historical data pack
- WHO: Ethics and governance of AI for health (2021)
Next outputs
The draft Index methodology and evidence register are available for challenge. Country scores will require indicator agreement, comparable data and independent review. MSI invites contributors through its research pathway.
Limits and disclosure
This briefing sets an institutional agenda rather than reporting empirical findings. Named institutions are sources, not MSI partners or endorsers. Funding and interests for any commissioned study will be recorded in that study. Suggested citation: Medicines Security Institute (2026), MSI Outlook 01: From architecture to evidence, 13 October.
Download briefing PDF